

## Supplementary material

# Metabolomics of COPD Pulmonary Rehabilitation Outcomes via Exhaled Breath Condensate

Mauro Maniscalco <sup>1,†,\*</sup>, Debora Paris <sup>2,†</sup>, Paola Cuomo <sup>2</sup>, Salvatore Fuschillo <sup>1</sup>, Pasquale Ambrosino <sup>3</sup>, Annabella Tramice <sup>2</sup>, Letizia Palomba <sup>4</sup> and Andrea Motta <sup>2,\*</sup>

<sup>1</sup> Istituti Clinici Scientifici Maugeri IRCCS, Pulmonary Rehabilitation Unit of Telese Terme Institute, 82037 Telese Terme, Italy; salvatore.fuschillo@icsmaugeri.it

<sup>2</sup> Institute of Biomolecular Chemistry, National Research Council, 80078 Pozzuoli, Italy; debora.paris@icb.cnr.it (D.P.); pao.cuomo@gmail.com (P.C.); annabella.tramice@icb.cnr.it (A.T.)

<sup>3</sup> Istituti Clinici Scientifici Maugeri IRCCS, Cardiac Rehabilitation Unit of Telese Terme Institute, 82037 Telese Terme, Italy; pasquale.ambrosino@icsmaugeri.it


<sup>4</sup> Department of Biomolecular Sciences, University of Urbino "Carlo Bo", 61029 Urbino, Italy; letizia.palomba@uniurb.it

\* Correspondence: mauro.maniscalco@icsmaugeri.it (M.M.); andrea.motta@icb.cnr.it (A.M.)


† These authors contributed equally to this work.

**Table S1.** Statistically significant discriminating metabolites in the T<sub>0</sub>-T<sub>5w</sub> OPLS-DA model of Figure 2A. The arrows indicate a decrease (↓) or an increase (↑) of the metabolite.


Metabolites	Chemical shift (δ, ppm)
Acetate ↓	1.93
Methanol ↓	3.39
3-Hydroxyisovalerate ↓	1.25; 2.37
Isobutyrate ↓	2.39
Acetone ↓	2.23
Isopropanol ↑	4.03
1-Propanol ↑	3.56
Lactate ↑	1.33
Fatty acids ↑	1.30




**Figure S1.** Box-and-whisker plots showing the concentration levels of discriminating metabolites in the T<sub>0</sub>-T<sub>2W</sub>-T<sub>5W</sub> and T<sub>0</sub>-T<sub>5W</sub> OPLS-DA models. (A) methanol at T<sub>0</sub>, T<sub>2W</sub> and T<sub>5W</sub>, (B) acetate at T<sub>0</sub> and T<sub>5W</sub>, (C) methanol at T<sub>0</sub> and T<sub>5W</sub>, and (D) 3-hydroxyisovalerate at T<sub>0</sub> and T<sub>5W</sub>. Boxes show median (horizontal line in each box), mean (the empty box), 25<sup>th</sup> and 75<sup>th</sup> percentiles (edges of box), maximum and minimum values (whiskers), and the outliers (cross). ANOVA test significance is reported as \*,  $p < 0.05$  and \*\*,  $p < 0.001$ .



**Figure S2.** Box-and-whisker plots showing the concentration levels of discriminating metabolites in the T<sub>0</sub>-T<sub>5W</sub> OPLS-DA model. (A) isopropanol, (B) 1-propanol, (C) lactate, and (D) fatty acids. Boxes show median (horizontal line in each box), mean (the empty box), 25<sup>th</sup> and 75<sup>th</sup> percentiles (edges of box), maximum and minimum values (whiskers), and the outliers (cross). ANOVA test significance is reported as \*,  $p < 0.05$  and \*\*,  $p < 0.001$ .



**Figure S3.** Plots of the YVar values for the three clinical parameters obtained from the OPLS model correlating NMR parameters and clinical outcomes. Variations of (A) dyspnea, (B) fatigue, and (C) 6MWT at T<sub>0</sub> (blue dots), T<sub>2w</sub> (gray dots), and T<sub>5w</sub> (red dots). Numbers on the x-axis refer to EBC samples of COPD patients involved in the study; the y-axis reports the variation (see main text).



**Figure S4.** Coefficient plots correlating metabolites uncovered in the NMR profile of EBC samples and the clinical rehabilitation parameters. Among all, methanol (3.39 ppm) showed the highest correlation with dyspnea (A), fatigue (B) and 6MWT (C), presenting high values of fatigue and dyspnea at T<sub>0</sub>. After 5 weeks of rehabilitation, methanol concentration decreased inversely with the lengths gained during the walk test, and proportionally with the low measures of fatigue and dyspnea reported for each patient.